OPKO Health, Inc. (NASDAQ:OPK) Given Average Rating of “Hold” by Analysts

OPKO Health, Inc. (NASDAQ:OPK) has earned an average rating of “Hold” from the six research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $1.55.

A number of equities research analysts have commented on the company. Wall Street Zen lowered OPKO Health from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Weiss Ratings upgraded OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 18th. Finally, Barrington Research lowered OPKO Health from an “outperform” rating to a “market perform” rating in a research report on Wednesday, April 29th.

OPKO Health Trading Up 2.1%

OPKO Health stock opened at $1.46 on Friday. The company has a 50 day moving average price of $1.18 and a 200 day moving average price of $1.24. OPKO Health has a 52 week low of $0.98 and a 52 week high of $1.60. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.17 and a current ratio of 3.61. The firm has a market capitalization of $1.10 billion, a price-to-earnings ratio of -5.41 and a beta of 1.42.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Tuesday, April 28th. The biotechnology company reported ($0.07) EPS for the quarter, hitting analysts’ consensus estimates of ($0.07). OPKO Health had a negative net margin of 36.63% and a negative return on equity of 16.78%. The firm had revenue of $124.20 million during the quarter, compared to analyst estimates of $130.51 million. During the same quarter last year, the business posted ($0.10) EPS. The company’s revenue was down 17.1% on a year-over-year basis. Research analysts forecast that OPKO Health will post -0.29 EPS for the current year.

Institutional Investors Weigh In On OPKO Health

A number of institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. boosted its stake in shares of OPKO Health by 150.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 5,986,913 shares of the biotechnology company’s stock valued at $7,544,000 after buying an additional 3,600,378 shares during the period. Millennium Management LLC boosted its stake in shares of OPKO Health by 39.2% during the 1st quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock valued at $10,602,000 after buying an additional 1,798,385 shares during the period. AQR Capital Management LLC boosted its stake in shares of OPKO Health by 466.7% during the 1st quarter. AQR Capital Management LLC now owns 1,608,906 shares of the biotechnology company’s stock valued at $2,671,000 after buying an additional 1,324,988 shares during the period. OP Asset Management Ltd acquired a new stake in shares of OPKO Health during the 1st quarter valued at $1,257,000. Finally, HRT Financial LP acquired a new stake in shares of OPKO Health during the 4th quarter valued at $851,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.